Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613066 | 0.90 | CYP3A4 (0.46) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL25624526 | 0.88 | CYP2C19 (0.40) | ALDH1A1KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL25613048 | 0.81 | TSHR (0.35) | — | |
| SCHEMBL25613054 | 0.79 | LTA4H (0.45) | ALDH1A1KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL25613041 | 0.79 | ADRA2A (0.33) | CYP2D6CYP2C19 | |
| SCHEMBL25624610 | 0.78 | CYP3A4 (0.42) | ALDH1A1CYP2D6 | |
| SCHEMBL25613042 | 0.76 | MAP3K7 (0.37) | SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL25613402 | 0.76 | CNR2 (0.36) | CYP1A2CYP2C19L3MBTL1TDP1 | |
| SCHEMBL25613175 | 0.75 | ADRA2A (0.37) | — | |
| SCHEMBL25613040 | 0.74 | MAPK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | ALDH1A1 3019/4885KDM4E 2788/4885CYP1A2 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.